NADAC acquisition cost data for NITROGLYCERIN 0.1 MG/HR PATCH. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00378910216 | $0.4789 | 2022-12-21 | Rx |
| 00378910293 | $0.4789 | 2022-12-21 | Rx |
| 43598089630 | $0.4789 | 2022-12-21 | Rx |
| 47781029603 | $0.4789 | 2022-12-21 | Rx |
| 00378910216 | $0.4789 | 2022-12-21 | Rx |
| 00378910293 | $0.4789 | 2022-12-21 | Rx |
| 43598089630 | $0.4789 | 2022-12-21 | Rx |
| 47781029603 | $0.4789 | 2022-12-21 | Rx |
Generic: Nitroglycerin | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $8.8M | 224,240 | 75,793 | $0.9098 |
| 2020 | $11.6M | 267,552 | 66,719 | $0.9160 |
| 2021 | $11.0M | 233,590 | 59,803 | $0.9551 |
| 2022 | $9.3M | 204,386 | 53,159 | $0.9025 |
| 2023 | $8.2M | 181,601 | 48,098 | $0.9046 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| Florida | $756.5K | 15,919 | 4,634 |
| New York | $732.6K | 19,196 | 4,670 |
| Texas | $586.9K | 11,939 | 3,489 |
| California | $491.5K | 10,019 | 2,982 |
| New Jersey | $376.6K | 7,345 | 1,967 |
| Tennessee | $337.9K | 7,550 | 2,092 |
| Illinois | $335.5K | 7,641 | 1,963 |
| Pennsylvania | $331.5K | 7,656 | 1,747 |
| Georgia | $321.5K | 7,058 | 1,999 |
| Ohio | $278.8K | 5,946 | 1,618 |
| North Carolina | $252.2K | 5,865 | 1,650 |
| Indiana | $251.0K | 5,482 | 1,510 |
| Wisconsin | $249.7K | 4,814 | 1,230 |
| Alabama | $238.8K | 4,976 | 1,491 |
| Massachusetts | $230.5K | 5,155 | 1,319 |
| Michigan | $178.7K | 3,579 | 1,054 |
| Maryland | $161.8K | 3,126 | 837 |
| Washington | $161.6K | 3,280 | 1,024 |
| Missouri | $135.7K | 2,941 | 814 |
| Puerto Rico | $133.1K | 3,177 | 820 |
| West Virginia | $130.6K | 2,810 | 724 |
| Kentucky | $128.3K | 3,477 | 791 |
| Virginia | $127.3K | 2,835 | 802 |
| Mississippi | $112.5K | 3,243 | 806 |
| South Carolina | $101.3K | 2,230 | 684 |
| Louisiana | $99.4K | 2,763 | 725 |
| Oklahoma | $94.7K | 2,110 | 632 |
| Connecticut | $89.8K | 1,812 | 464 |
| Oregon | $87.2K | 1,896 | 518 |
| Kansas | $76.2K | 2,147 | 452 |
| South Dakota | $68.5K | 1,694 | 363 |
| Arizona | $66.3K | 1,280 | 439 |
| Nebraska | $64.7K | 1,314 | 242 |
| Minnesota | $49.9K | 1,011 | 283 |
| Maine | $44.5K | 840 | 215 |
| Arkansas | $42.4K | 1,030 | 245 |
| Iowa | $36.1K | 912 | 214 |
| Colorado | $29.2K | 661 | 195 |
| Hawaii | $28.6K | 535 | 135 |
| Nevada | $27.8K | 571 | 201 |
| North Dakota | $22.7K | 587 | 119 |
| District of Columbia | $20.4K | 326 | 103 |
| Rhode Island | $20.1K | 383 | 93 |
| New Mexico | $18.4K | 402 | 123 |
| Delaware | $14.3K | 269 | 74 |
| Idaho | $13.5K | 342 | 92 |
| New Hampshire | $13.2K | 282 | 83 |
| Utah | $11.6K | 301 | 120 |
| Alaska | $10.7K | 156 | 53 |
| Vermont | $10.4K | 256 | 90 |
| Montana | $8.8K | 237 | 55 |
| Virgin Islands | $3.4K | 57 | 11 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.